A probiotic-coated oral delivery system protected the bee venom peptide melittin from stomach acid and delivered it to gut immune centers, rebalancing the immune system to alleviate rheumatoid arthritis in animal models.
Oral venom peptide → gut immune rebalancingProbiotic-coated melittin nanoparticles survived stomach acid, accumulated in mesenteric lymph nodes, and rebalanced Th17/Treg and Th1/Th2 immune cell ratios to alleviate rheumatoid arthritis
What the researchers found
Researchers created an oral delivery system for melittin — a bee venom peptide with anti-arthritic properties — by encapsulating it in a multi-layered micro-nano system. Sialic acid-decorated melittin nanoparticles were embedded in calcium alginate microgels, then coated with probiotic biofilms. This probiotic coating protected melittin from stomach acid destruction and helped it adhere to the intestinal wall.
The system accumulated in mesenteric lymph nodes (gut immune centers) and modulated key immune cell ratios — Th1/Th2 and Th17/Treg — in both lymph nodes and spleen tissue. This rebalancing of the immune system successfully alleviated arthritis progression in the animal model while reducing the off-target adverse effects that normally limit melittin's clinical use.
Why it matters
Rheumatoid arthritis requires lifelong treatment, and current drugs either suppress the immune system broadly (causing infections) or are expensive biologics that require injection. Melittin from bee venom has shown anti-arthritic immune-modulating effects, but it's destroyed by stomach acid and can be toxic when not targeted properly. This study solves both problems with an elegant triple-layer delivery system that protects the peptide, targets it to gut immune centers, and uses the gut-immune axis to treat a systemic autoimmune disease. If the concept works in humans, it could turn a venom peptide into an oral autoimmune therapy.
The numbers in context
Melittin: bee venom peptide · sialic acid-decorated nanomedicines · calcium alginate microgels · probiotic biofilm coating · targets mesenteric lymph nodes · modulates Th1/Th2 and Th17/Treg ratios · alleviates arthritis progression
How the study worked
Gas-shearing microfluidics was used to create monodisperse sialic acid-decorated melittin nanoparticles within calcium alginate microgels. The microspheres were coated with probiotic biofilms for acid resistance and intestinal adhesion. The system was administered orally to an animal model of rheumatoid arthritis. Immune cell ratios (Th1/Th2, Th17/Treg) were measured in mesenteric lymph nodes and spleen. Arthritis progression and adverse effects were assessed.
Who was studied
Animal model of rheumatoid arthritis
What this study cannot tell us
This is a preclinical animal study with no human data. The multi-component delivery system is complex to manufacture, which could limit scalability and clinical translation. Long-term safety of repeated oral probiotic biofilm-coated nanoparticles is unknown. The specific animal arthritis model used is not described in the abstract. Melittin's known toxicity at higher doses remains a concern even with targeted delivery.
How to read the evidence
This study is graded as preliminary. While the delivery technology is innovative and the immune modulation results are promising, all data comes from animal models. The manufacturing complexity and melittin's known toxicity profile present additional hurdles before clinical translation.
When this study was published
Published in 2026, this is a brand-new study at the frontier of oral peptide delivery and gut-immune axis therapeutics for autoimmune disease.
The bigger picture
This study connects three converging research trends: venom-derived peptide therapeutics, the gut-immune axis, and probiotic-based drug delivery. The insight that gut immune centers can be targeted to treat a systemic autoimmune disease is powerful — it suggests that many autoimmune conditions could be treated through gut-targeted oral therapies rather than systemic immunosuppression. The probiotic biofilm coating is a particularly creative innovation, using bacteria's natural survival mechanisms to protect and deliver a therapeutic peptide.
Questions still open
- Could this probiotic-coated oral delivery system be adapted for other autoimmune diseases like multiple sclerosis or inflammatory bowel disease?
- How does the long-term safety of repeated oral melittin delivery compare to current RA biologics like TNF inhibitors?
- Would this gut-targeted immune modulation approach work for other venom-derived peptides with anti-inflammatory properties?
Common questions
How can bee venom help with arthritis?
Why coat the nanoparticles with probiotic bacteria?
Read the original research
Oral administration of probiotic colony-like micro-nano system for immunoregulation of rheumatoid arthritis.
Acta pharmaceutica Sinica. B, 16(1), 444-457
Citation
Zhang, Fangke; Ding, Tao; Zheng, Jiancheng; Li, Nan; Li, Zechuan; Wang, Xuefei; Du, Yawei; Hu, Weiguo; Cui, Wenguo; Guo, Weisheng. (2026). Oral administration of probiotic colony-like micro-nano system for immunoregulation of rheumatoid arthritis.. Acta pharmaceutica Sinica. B, 16(1), 444-457. https://doi.org/10.1016/j.apsb.2025.10.038